Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Exosomes and Microvesicles

Anastasia Khvorova's Biography



Anastasia Khvorova, Professor, RNA Therapeutics Institute, University of Massachusetts Medical School

Anastasia Khvorova, PhD, is Professor in the RNA Therapeutics Institute and the Program in Molecular Medicine at the University of Massachusetts Medical School (UMMS) in Worcester, Massachusetts. Before joining the UMMS faculty, she held leadership positions in industry, including Vice President of Research & Development and Chief Science Officer of Dharmacon, Founder and Scientific Advisor of Advirna, and Chief Science Officer and Senior Vice President of RXi Pharmaceuticals. Dr Khvorova’s industry experience in drug discovery and development collaborations with pharmaceutical companies along with her expertise in chemistry and cell biology allowed her to establish a lab at UMMS that brings together organic chemists and RNA biologists to develop novel approaches and solutions to understanding natural and therapeutic RNA trafficking and delivery. Dr Khvorova is a member of the Board of Directors of the Oligonucleotide Therapeutics Society and sits on the editorial board of Nucleic Acid Research. She is the author of more than 150 abstracts, more than 50 peer-reviewed articles, several book chapters, and more than 250 patents and patent applications; her publications are widely cited.

Anastasia Khvorova Image

Exosome Mediated Delivery of Therapeutic Oligonucleotides for Treatment of Neurodegenerative Disorders

Monday, 23 March 2015 at 17:30

Add to Calendar ▼2015-03-23 17:30:002015-03-23 18:30:00Europe/LondonExosome Mediated Delivery of Therapeutic Oligonucleotides for Treatment of Neurodegenerative DisordersSELECTBIOenquiries@selectbiosciences.com

Oligonucleotide therapeutics is a new class of drugs, the clinical utility of which has been limited by inefficient tissue distribution and cellular uptake. Through our research, we have developed a novel methodology that enables the loading of hydrophobically modified oligonucleotides (hsiRNA) into exosomes. These hsiRNAs show efficient cellular uptake in vitro as well as broad brain distribution and in vivo efficacy. Exosome-formulated oligonucleotide therapeutics might be a solution for the development of novel therapeutics for the treatment of neurodegenerative disorders.


Add to Calendar ▼2015-03-23 00:00:002015-03-24 00:00:00Europe/LondonExosomes and MicrovesiclesSELECTBIOenquiries@selectbiosciences.com